Novartis to acquire Chinook Therapeutics for up to USD 3.5 billion in boost to late stage pipeline

Published On 2023-06-12 07:30 GMT   |   Update On 2023-06-12 07:30 GMT
Advertisement

Basel: Novartis said on Monday it agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to USD 3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.

The transaction, in the form of a merger of a newly formed Novartis subsidiary and Chinook, is expected to close in the second half of 2023, the Swiss drugmaker said in a statement.

Advertisement

Under the agreed deal, Chinook shareholders would receive $3.2 billion, or $40 per share, in cash plus a contingent value right worth up to $300 million, depending on certain regulatory achievements, it said.

Read also: Novartis Kisqali significantly reduced risk of recurrence by 25% across broad population of patients with early breast cancer: Novartis

The U.S. biotech firm expects to see the pivotal readout in the fourth quarter of this year of a clinical trial in the third and last stage of development of oral drug candidate atrasentan to treat a kidney disease known as IgAN.

Chinook also has zigakibart, another experimental IgAN treatment, under development and plans to start a Phase 3 in the third quarter of 2023.

Read also: Novartis sees Sandoz adding USD 3 billion in net sales over next five years


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News